IGM Biosciences Statistics
Total Valuation
IGM Biosciences has a market cap or net worth of $76.57 million. The enterprise value is -$27.73 million.
Important Dates
The last earnings date was Thursday, July 31, 2025, after market close.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IGM Biosciences has 60.29 million shares outstanding. The number of shares has increased by 1.64% in one year.
| Current Share Class | 36.59M |
| Shares Outstanding | 60.29M |
| Shares Change (YoY) | +1.64% |
| Shares Change (QoQ) | +0.96% |
| Owned by Insiders (%) | 2.53% |
| Owned by Institutions (%) | 11.63% |
| Float | 12.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.53 |
| Forward PS | 4.09 |
| PB Ratio | 0.76 |
| P/TBV Ratio | 0.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.66
| Current Ratio | 17.66 |
| Quick Ratio | 17.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -47.82% and return on invested capital (ROIC) is 4.88%.
| Return on Equity (ROE) | -47.82% |
| Return on Assets (ROA) | 2.89% |
| Return on Invested Capital (ROIC) | 4.88% |
| Return on Capital Employed (ROCE) | 10.17% |
| Revenue Per Employee | $973,490 |
| Profits Per Employee | -$358,289 |
| Employee Count | 149 |
| Asset Turnover | 0.65 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.62% in the last 52 weeks. The beta is 0.59, so IGM Biosciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -85.62% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 3.65 |
| Relative Strength Index (RSI) | 47.94 |
| Average Volume (20 Days) | 488,861 |
Short Selling Information
The latest short interest is 452,126, so 0.75% of the outstanding shares have been sold short.
| Short Interest | 452,126 |
| Short Previous Month | 404,560 |
| Short % of Shares Out | 0.75% |
| Short % of Float | 3.51% |
| Short Ratio (days to cover) | 0.38 |
Income Statement
In the last 12 months, IGM Biosciences had revenue of $145.05 million and -$53.39 million in losses. Loss per share was -$0.88.
| Revenue | 145.05M |
| Gross Profit | -5.49M |
| Operating Income | 10.26M |
| Pretax Income | -236.33M |
| Net Income | -53.39M |
| EBITDA | 17.63M |
| EBIT | 10.26M |
| Loss Per Share | -$0.88 |
Full Income StatementBalance Sheet
The company has $104.31 million in cash and n/a in debt, giving a net cash position of $104.31 million or $1.73 per share.
| Cash & Cash Equivalents | 104.31M |
| Total Debt | n/a |
| Net Cash | 104.31M |
| Net Cash Per Share | $1.73 |
| Equity (Book Value) | 100.93M |
| Book Value Per Share | 1.68 |
| Working Capital | 100.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$156.51 million and capital expenditures -$2.19 million, giving a free cash flow of -$158.70 million.
| Operating Cash Flow | -156.51M |
| Capital Expenditures | -2.19M |
| Free Cash Flow | -158.70M |
| FCF Per Share | -$2.63 |
Full Cash Flow StatementMargins
Gross margin is -3.79%, with operating and profit margins of 7.07% and -36.80%.
| Gross Margin | -3.79% |
| Operating Margin | 7.07% |
| Pretax Margin | -36.80% |
| Profit Margin | -36.80% |
| EBITDA Margin | 12.16% |
| EBIT Margin | 7.07% |
| FCF Margin | n/a |
Dividends & Yields
IGM Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.64% |
| Shareholder Yield | -1.64% |
| Earnings Yield | -69.72% |
| FCF Yield | -207.26% |
Analyst Forecast
The average price target for IGM Biosciences is $6.00, which is 372.44% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.00 |
| Price Target Difference | 372.44% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 2.97% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IGM Biosciences has an Altman Z-Score of 28.83 and a Piotroski F-Score of 4.
| Altman Z-Score | 28.83 |
| Piotroski F-Score | 4 |